Home Blog of Signal Transduction DNA Damage/DNA Repair MDM2/MDMX

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

MDM2/MDMX

Role of parthenolide in paclitaxel-induced oxidative stress injury and impaired reproductive function in rat testicular tissue

564 views | Dec 28 2023

Parthenolide treatment in rats demonstrated a dose-dependent mitigation of oxidative stress-induced testicular damage caused by paclitaxel, showing promise as a potential therapeutic avenue for addressing testicular toxicity and supporting reproductive function. [Read the Full Post]

Improving Speed and Affordability without Compromising Accuracy: Standard Binding Free-Energy Calculations Using an Enhanced Sampling Algorithm, Multiple-Time Stepping, and Hydrogen Mass Repartitioning

188 views | Dec 21 2023

The study proposes an accelerated computational strategy, combining longer time steps with hydrogen-mass repartitioning and multiple time-stepping, to efficiently calculate protein-ligand binding free energies using well-tempered metadynamics, significantly reducing computational time without compromising accuracy. [Read the Full Post]

Senolytic Combination Treatment Is More Potent Than Single Drugs in Reducing Inflammatory and Senescence Burden in Cells from Painful Degenerating IVDs

212 views | Nov 09 2023

Combining the senolytic drugs o-Vanillin and RG-7112 effectively removes senescent cells, reduces inflammation and pain mediators, and inhibits neuronal sprouting, offering promise as a potential treatment for low back pain associated with intervertebral disc degeneration. [Read the Full Post]

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

181 views | Aug 14 2023

The combination of siremadlin and ribociclib showed manageable toxicity and early signs of antitumor activity in patients with advanced well-differentiated or dedifferentiated liposarcoma. [Read the Full Post]

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III

265 views | Aug 14 2023

The study utilized PBPK/PD modeling and virtual clinical trial simulations to evaluate the potential efficacy of the siremadlin and trametinib combination as a therapy for melanoma, based on in vitro studies and in vivo extrapolation. [Read the Full Post]

Three dimensional models of dedifferentiated liposarcoma cell lines: scaffold-based and scaffold-free approaches

329 views | Jun 20 2023

This study aimed to establish 3D cell culture models of liposarcomas using different methods, observing distinct structural differences and demonstrating the potential of these models to provide new insights into efficacy and toxicity, serving as an important step in the pre-clinical phase prior to clinical trials. [Read the Full Post]

MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1

244 views | Jun 19 2023

MI-773, a specific antagonist of MDM2, disrupts the MDM2/p53 axis, leading to suppressed proliferation, induced apoptosis, and cell cycle arrest in neuroblastoma cells, suggesting its potential as a novel treatment strategy for this pediatric malignancy. [Read the Full Post]

Insights into the mechanisms of triptolide nephrotoxicity through network pharmacology-based analysis and RNA-seq

451 views | Apr 19 2023

The combination of network pharmacology and deep RNA-seq analysis provides valuable insights into the molecular mechanisms of TPL nephrotoxicity, identifying potential targets and signaling pathways for further investigation. [Read the Full Post]

Chlorogenic acid, rutin, and quercetin from Lysimachia christinae alleviate triptolide-induced multi-organ injury in vivo by modulating immunity and AKT/mTOR signal pathway to inhibit ferroptosis and apoptosis

483 views | Apr 18 2023

The study showed that a combination of organ-protective ingredients from Lysimachia christinae could protect against triptolide-induced multi-organ injury in vivo by activating the AKT/mTOR pathway and reducing cell death including ferroptosis and apoptosis inhibition. [Read the Full Post]

The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines

195 views | Dec 05 2022

Simone Patergnani et al. found that the targeting of MDM2 by RG7112 might represent a new therapeutic option for the treatment of ADPKD. [Read the Full Post]